We are live on ! Find out more
SRPT icon

Sarepta Therapeutics

177 hedge funds and large institutions have $1.08B invested in Sarepta Therapeutics in 2016 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 63 increasing their positions, 54 reducing their positions, and 50 closing their positions.

New
Increased
Maintained
Reduced
Closed

72.29% more ownership

Funds ownership: 0%72.29% (+72%)

17% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 54

9% more call options, than puts

Call options by funds: $212M | Put options by funds: $195M

5% less funds holding

Funds holding: 186177 (-9)

14% less first-time investments, than exits

New positions opened: 43 | Existing positions closed: 50

58% less capital invested

Capital invested by funds: $2.59B → $1.08B (-$1.51B)

64% less funds holding in top 10

Funds holding in top 10: 114 (-7)

Holders
177
Holders Change
-9
Holders Change %
-4.84%
% of All Funds
4.42%
Holding in Top 10
4
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-63.64%
% of All Funds
0.1%
New
43
Increased
63
Reduced
54
Closed
50
Calls
$212M
Puts
$195M
Net Calls
+$17.1M
Net Calls Change
+$274M
Name Holding Trade Value Shares
Change
Change in
Stake
ProShare Advisors
76
ProShare Advisors
Maryland
$1.21M +$365K +9,080 +26%
AQR Capital Management
77
AQR Capital Management
Connecticut
$1.14M +$1.48M +36,738 +738%
HighTower Advisors
78
HighTower Advisors
Illinois
$1.13M +$423K +10,540 +34%
NFA
79
Nationwide Fund Advisors
Ohio
$1.1M +$161K +4,004 +11%
IGIM
80
I.G. Investment Management
Manitoba, Canada
$1.1M +$1.61M +40,000 New
American Century Companies
81
American Century Companies
Missouri
$1.03M +$2.17K +54 +0.1%
HT
82
HAP Trading
New York
$1M +$1.47M +36,556 New
SIM
83
Spark Investment Management
New York
$987K +$1.45M +36,000 New
MLICM
84
Metropolitan Life Insurance Company (MetLife)
New York
$974K +$149K +3,717 +12%
Manulife (Manufacturers Life Insurance)
85
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$935K +$193K +4,802 +16%
SG Americas Securities
86
SG Americas Securities
New York
$929K +$1.08M +26,816 +380%
Macquarie Group
87
Macquarie Group
Australia
$905K +$1.33M +33,000 New
LCM
88
Landscape Capital Management
New Jersey
$882K +$1.29M +32,162 New
BBHC
89
Brown Brothers Harriman & Co
New York
$860K
VEA
90
Virtus ETF Advisers
New York
$856K +$734K +18,266 +141%
HCM
91
Highbridge Capital Management
New York
$845K -$298K -7,410 -19%
D.E. Shaw & Co
92
D.E. Shaw & Co
New York
$814K +$1.19M +29,684 New
FO
93
FT Options
Illinois
$797K -$801K -19,951 -41%
SAM
94
Sectoral Asset Management
Quebec, Canada
$790K +$1.16M +28,799 New
First Trust Advisors
95
First Trust Advisors
Illinois
$780K +$1.14M +28,451 New
Citigroup
96
Citigroup
New York
$763K -$41K -1,020 -4%
DekaBank Deutsche Girozentrale
97
DekaBank Deutsche Girozentrale
Germany
$758K +$80.3K +2,000 +8%
State Board of Administration of Florida Retirement System
98
State Board of Administration of Florida Retirement System
Florida
$740K -$70.3K -1,750 -6%
UCFA
99
United Capital Financial Advisors
Texas
$698K -$40 -1 -0%
AIG
100
American International Group
New York
$674K -$2.57K -64 -0.3%

SRPT Hedge Fund Activity: Q4 2016 in Review

177 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q4 2016, worth a combined $1.08B — down 58% from $2.59B a quarter earlier.

Sellers outnumbered buyers: 50 funds closed out of SRPT and 43 opened new positions — a net loss of 7 holders — while 54 trimmed existing stakes and 63 added.

The largest buyer was Carlson Capital, opening a new position worth an estimated $88.5M. The largest seller was Point72 Asset Management, cutting an estimated $77M.

  • 177 institutional investors held Sarepta Therapeutics (SRPT) as of Q4 2016, down from 186 in Q3 2016.
  • Funds reported $1.08B of Sarepta Therapeutics stock for Q4 2016, down 58% quarter-over-quarter.
  • 43 funds opened new Sarepta Therapeutics positions in Q4 2016 and 50 closed out, a net change of -7 holders.
  • The largest Sarepta Therapeutics buyer in Q4 2016 was Carlson Capital, an estimated $88.5M added.
  • The largest Sarepta Therapeutics seller in Q4 2016 was Point72 Asset Management, an estimated $77M sold.

Based on aggregated 13F filings for Q4 2016.